Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. XYZResearch published a report for global Gastric Cancer Testing Treatment and Prevention market in this environment.
In terms of revenue, this research report indicated that the global Gastric Cancer Testing Treatment and Prevention market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Gastric Cancer Testing Treatment and Prevention industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Bristol Myers Squibb aims at producing XX Gastric Cancer Testing Treatment and Prevention in 2020, with XX % production to take place in global market, Eli Lilly And Company accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Gastric Cancer Testing Treatment and Prevention Market by XYZResearch Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Gastric Cancer Testing Treatment and Prevention Market?
Bristol Myers Squibb
Eli Lilly And Company
Glaxosmithkline Genentech
Roche
Immunogen Merck & Company
Novartis
Pacific Edge Diagnostics Nz
Pfizer
Roche/Genentech Oncolytics
Zova Biotherapeutics
...
Major Type of Gastric Cancer Testing Treatment and Prevention Covered in XYZResearch report:
Test
Treatment
Prevention
Application Segments Covered in XYZResearch Market
Hospitals
Clinics
Other
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Gastric Cancer Testing Treatment and Prevention Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 Test -Product Introduction and Major Manufacturers
1.1.2 Treatment -Product Introduction and Major Manufacturers
1.1.3 Prevention -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Gastric Cancer Testing Treatment and Prevention Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)
2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)
3 Regional Market Analysis
3.1 China Gastric Cancer Testing Treatment and Prevention Market
3.1.1 Top Companies leading Gastric Cancer Testing Treatment and Prevention Development in China (2015-2020)
3.1.2 Sales Value of Major Company in China Market (2015-2020)
3.1.3 China Gastric Cancer Testing Treatment and Prevention Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2015-2026)
3.2 EU Gastric Cancer Testing Treatment and Prevention Market
3.2.1 Top Companies leading Gastric Cancer Testing Treatment and Prevention Development in EU (2015-2020)
3.2.2 Sales Value of Major Company in EU Market (2015-2020)
3.2.3 EU Gastric Cancer Testing Treatment and Prevention Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2015-2026)
3.3 USA Gastric Cancer Testing Treatment and Prevention Market
3.3.1 Top Companies leading Gastric Cancer Testing Treatment and Prevention Development in USA (2015-2020)
3.3.2 Sales Value of Major Company in USA Market (2015-2020)
3.3.3 USA Gastric Cancer Testing Treatment and Prevention Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2015-2026)
3.4 Japan Gastric Cancer Testing Treatment and Prevention Market
3.4.1 Top Companies leading Gastric Cancer Testing Treatment and Prevention Development in Japan (2015-2020)
3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
3.4.3 Japan Gastric Cancer Testing Treatment and Prevention Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2015-2026)
3.5 India Gastric Cancer Testing Treatment and Prevention Market
3.5.1 Top Companies leading Gastric Cancer Testing Treatment and Prevention Development in India (2015-2020)
3.5.2 Sales Value of Major Company in India Market (2015-2020)
3.5.3 India Gastric Cancer Testing Treatment and Prevention Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2015-2026)
3.6 Southeast Asia Gastric Cancer Testing Treatment and Prevention Market
3.6.1 Top Companies leading Gastric Cancer Testing Treatment and Prevention Development in Southeast Asia (2015-2020)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
3.6.3 Southeast Asia Gastric Cancer Testing Treatment and Prevention Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
3.7 South America Gastric Cancer Testing Treatment and Prevention Market
3.7.1 Top Companies leading Gastric Cancer Testing Treatment and Prevention Development in South America (2015-2020)
3.7.2 Sales Value of Major Company in South America Market (2015-2020)
3.7.3 South America Gastric Cancer Testing Treatment and Prevention Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2015-2026)
4 Value Chain (Impact of COVID-19)
4.1 Gastric Cancer Testing Treatment and Prevention Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Gastric Cancer Testing Treatment and Prevention Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2026)
5.1 Global Gastric Cancer Testing Treatment and Prevention Sales and Growth Rate (2021-2026)
5.2 Global Gastric Cancer Testing Treatment and Prevention Sales Value and Growth Rate (2021-2026)
6 Gastric Cancer Testing Treatment and Prevention Competitive Analysis
6.1 Bristol Myers Squibb
6.1.1 Bristol Myers Squibb Company Profiles
6.1.2 Bristol Myers Squibb Product Introduction
6.1.3 Bristol Myers Squibb Gastric Cancer Testing Treatment and Prevention Production, Revenue (2015-2020)
6.1.4 SWOT Analysis
6.2 Eli Lilly And Company
6.2.1 Eli Lilly And Company Company Profiles
6.2.2 Eli Lilly And Company Product Introduction
6.2.3 Eli Lilly And Company Gastric Cancer Testing Treatment and Prevention Production, Revenue (2015-2020)
6.2.4 SWOT Analysis
6.3 Glaxosmithkline Genentech
6.3.1 Glaxosmithkline Genentech Company Profiles
6.3.2 Glaxosmithkline Genentech Product Introduction
6.3.3 Glaxosmithkline Genentech Gastric Cancer Testing Treatment and Prevention Production, Revenue (2015-2020)
6.3.4 SWOT Analysis
6.4 Roche
6.4.1 Roche Company Profiles
6.4.2 Roche Product Introduction
6.4.3 Roche Gastric Cancer Testing Treatment and Prevention Production, Revenue (2015-2020)
6.4.4 SWOT Analysis
6.5 Immunogen Merck & Company
6.5.1 Immunogen Merck & Company Company Profiles
6.5.2 Immunogen Merck & Company Product Introduction
6.5.3 Immunogen Merck & Company Gastric Cancer Testing Treatment and Prevention Production, Revenue (2015-2020)
6.5.4 SWOT Analysis
6.6 Novartis
6.6.1 Novartis Company Profiles
6.6.2 Novartis Product Introduction
6.6.3 Novartis Gastric Cancer Testing Treatment and Prevention Production, Revenue (2015-2020)
6.6.4 SWOT Analysis
6.7 Pacific Edge Diagnostics Nz
6.7.1 Pacific Edge Diagnostics Nz Company Profiles
6.7.2 Pacific Edge Diagnostics Nz Product Introduction
6.7.3 Pacific Edge Diagnostics Nz Gastric Cancer Testing Treatment and Prevention Production, Revenue (2015-2020)
6.7.4 SWOT Analysis
6.8 Pfizer
6.8.1 Pfizer Company Profiles
6.8.2 Pfizer Product Introduction
6.8.3 Pfizer Gastric Cancer Testing Treatment and Prevention Production, Revenue (2015-2020)
6.8.4 SWOT Analysis
6.9 Roche/Genentech Oncolytics
6.9.1 Roche/Genentech Oncolytics Company Profiles
6.9.2 Roche/Genentech Oncolytics Product Introduction
6.9.3 Roche/Genentech Oncolytics Gastric Cancer Testing Treatment and Prevention Production, Revenue (2015-2020)
6.9.4 SWOT Analysis
6.10 Zova Biotherapeutics
6.10.1 Zova Biotherapeutics Company Profiles
6.10.2 Zova Biotherapeutics Product Introduction
6.10.3 Zova Biotherapeutics Gastric Cancer Testing Treatment and Prevention Production, Revenue (2015-2020)
6.10.4 SWOT Analysis
7 Conclusion
| Price : US$ 3500 |
Date : Dec 2024 |
| Category : Automotive |
Pages : 167 |
Request Sample 
Request Discount 
Inquire Before Buy
